Business Wire

MA-WASABI-TECHNOLOGIES

Share
Wasabi Technologies Reinforces its Commitment to EMEA with the Appointment of Jon Howes as General Manager

Wasabi Technologies, the hot cloud storage company, strengthened its foothold in EMEA with the appointment of Jon Howes as Vice President and General Manager for EMEA. Howes will build on Wasabi’s momentous growth in the region, highlighted by a flagship deal with Liverpool Football Club, 1,800 new partners, and a nearly 90% ARR growth rate. Additionally, a full region go-to-market team has been established to support the growth of cloud storage, with Eric Peters as Country Manager of Benelux & Southern Europe based in France; Daniel Arabié, Country Manager of Central Europe/DACH based in Germany, and Kevin Dunn, Country Manager for the UK/I & Nordics based in the UK.

Jon Howes, VP and GM for EMEA, Wasabi Technologies, said: 
“Demand for predictably priced, secure, high-performance cloud storage is growing at an unprecedented pace in EMEA, making Wasabi a perfect fit for the market. Our immense traction across Europe is a testament to the value we bring to enterprises and organisations across sports, media and entertainment, surveillance, education, healthcare, and more. Being at the helm of Wasabi’s EMEA operations is a once-in-a-lifetime opportunity, and I look forward to the expansion of Wasabi hot cloud storage in this important region along with our industry-leading team.”

Howes brings more than 20 years’ experience to Wasabi, with deep expertise in scaling go-to-market models for technology companies in EMEA including Juniper Networks, Oracle and Infovista. His initial priorities will be growing Wasabi’s channel presence, scaling its partner and customer base, and strategically increasing Wasabi’s headcount in key European markets, specifically the UK, France and Germany. Meanwhile, Wasabi’s newly appointed country managers hold a plethora of proven sales and channel experience with organisations including AWS, Cloudian, EMC, Juniper Networks, Nimble Storage, and others.

Wasabi’s 'channel-first’ approach in EMEA has established partnerships with Exclusive Networks, Ebertlang, Veeam, Equinix, and more – most recently Skill Partner. Marquee customer wins include Liverpool Football Club, who migrated to Wasabi for predictable, affordable cloud storage without fees for egress or API requests in order to create a central repository for all the club’s digital media.

Drew Crisp, SVP of Digital at Liverpool Football Club, said: 
“Many cloud vendors try to be all things to all people, to the customer’s detriment. Wasabi’s singular focus on cloud storage has made them brilliant at what they do. They know the cloud storage space inside and out and have worked with us every step of the way. Not only does Liverpool FC have a very simple cost model with Wasabi as we migrate from on-premises to the cloud, we have price predictability that enables us to truly understand our total cost of ownership, which is essential for us.”

Arnaud Semont, Associate Director at Skill Partner, said: 
“Skill Partner goes to market with innovative, disruptive and predictable IT solutions, which is why we partner with Wasabi on our backup and disaster recovery services. We use Wasabi cloud storage to keep an external copy of our customers' data using immutable storage, which ensures data is safe from ransomware with object lock. As a system integrator and service provider based in EMEA, Wasabi's local storage regions help us meet data sovereignty requirements, allowing us to use the Wasabi Paris storage region with replication to Frankfurt.”

Wasabi hot cloud storage is the industry’s most reliable, scalable, and predictably priced cloud storage with no fees for egress or API requests and no vendor lock-in. Wasabi is gaining market traction at a phenomenal pace as organisations globally are looking for cloud storage solutions that fit their budgets and unique needs. It’s also an ideal product for the channel because every organisation needs to store data and Wasabi is simple to understand and integrate with other best-of-breed products. It also offers the highest level of protection in cloud storage with Object Lock immutability and 11 x 9s of data durability. Service launched in EMEA in 2019 with the opening of the Amsterdam storage region. Since then, Wasabi has added storage regions in London, Frankfurt, and Paris to support the company’s rapid growth and to meet customer data sovereignty needs.

Companies in every industry can benefit from Wasabi hot cloud storage and its suite of supporting products and tools like the recently announced Wasabi Surveillance Cloud, which delivers bottomless storage for video surveillance, and a state-of-the-art Carbon Footprint Calculator that helps customers and partners accurately measure and report on their energy use in specific Wasabi data centres as part of their broader ESG objectives.

Regularly named one of technology’s fastest-growing companies, and recognized by analysts as the top alternative to AWS S3, Wasabi has raised over $500 million in funding to support its international expansion and availability for customers of every size. For more information on how Wasabi can partner with your organisation, visit here or contact emeasales@wasabi.com.

About Wasabi Technologies 
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organisations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.

Follow and connect with Wasabi on Linkedin,Twitter, Facebook, Instagram, and The Bucket.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye